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ABSTRACT
Background
Muscular insulin resistance is frequently characterized by blunted increases in glucose-6-
phosphate (G-6-P) reflecting impaired glucose transport/phosphorylation. These abnormalities
likely relate to excessive intramyocellular lipids and mitochondrial dysfunction. We
hypothesized that alterations in insulin action and mitochondrial function should be present
even in nonobese patients with well-controlled type 2 diabetes mellitus (T2DM).
Methods and Findings
We measured G-6-P, ATP synthetic flux (i.e., synthesis) and lipid contents of skeletal muscle
with
31P/
1H magnetic resonance spectroscopy in ten patients with T2DM and in two control
groups: ten sex-, age-, and body mass-matched elderly people; and 11 younger healthy
individuals. Although insulin sensitivity was lower in patients with T2DM, muscle lipid contents
were comparable and hyperinsulinemia increased G-6-P by 50% (95% confidence interval [CI]
39%–99%) in all groups. Patients with diabetes had 27% lower fasting ATP synthetic flux
compared to younger controls (p¼0.031). Insulin stimulation increased ATP synthetic flux only
in controls (younger: 26%, 95% CI 13%–42%; older: 11%, 95% CI 2%–25%), but failed to increase
even during hyperglycemic hyperinsulinemia in patients with T2DM. Fasting free fatty acids
and waist-to-hip ratios explained 44% of basal ATP synthetic flux. Insulin sensitivity explained
30% of insulin-stimulated ATP synthetic flux.
Conclusions
Patients with well-controlled T2DM feature slightly lower flux through muscle ATP synthesis,
which occurs independently of glucose transport /phosphorylation and lipid deposition but is
determined by lipid availability and insulin sensitivity. Furthermore, the reduction in insulin-
stimulated glucose disposal despite normal glucose transport/phosphorylation suggests
further abnormalities mainly in glycogen synthesis in these patients.
The Editors’ Summary of this article follows the references.
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Skeletal muscle insulin resistance is characteristic in the
elderly as well as in persons at increased risk of type 2
diabetes mellitus (T2DM) and those with overt T2DM. In
these groups, the content of intramyocellular lipids (IMCL) is
frequently increased and related to insulin resistance [1,2].
However, this relationship disappears during exercise train-
ing, which increases both IMCL and insulin sensitivity in
parallel [3,4]. Rather than IMCL, intracellular metabolites of
free fatty acids (FFAs), such as long-chain fatty acyl coenzyme
A and diacylglycerol, inhibit insulin action by stimulating
phosphorylation of serine residues of insulin receptor
substrate-1 (IRS-1) [5]. This suggests that IMCL do not
directly contribute to insulin resistance but accumulate as a
consequence of increased lipid availability from augmented
lipolysis and excess dietary fat supply and/or of impaired
mitochondrial lipid oxidation [6].
In severe obesity and moderately controlled T2DM, insulin
resistance has been linked to abnormal mitochondrial
function of skeletal muscle as assessed by in vitro and ex
vivo examination in biopsies [7–9]. Application of magnetic
resonance spectroscopy (MRS) made it possible to non-
invasively examine myocellular mitochondrial function by
measuring rates of ATP synthesis (‘‘synthetic ﬂux’’) in humans
[10]. Insulin resistant elderly people and ﬁrst-degree relatives
of patients with T2DM have impaired muscle ATP production
and elevated IMCL [11,12]. These studies raised the questions
of (i) whether lipid accumulation in skeletal muscle and/or
insulin resistance promotes mitochondrial dysfunction and, if
so, (ii) whether insulin stimulation can overcome such
alterations. In this context, we recently showed that short-
term elevation of plasma FFAs profoundly inhibits insulin-
stimulated glucose transport/phosphorylation and mitochon-
drial function, reﬂected by diminished increase in intra-
myocellular glucose-6-phosphate (G-6-P) and ATP synthesis,
independently of ectopic muscle fat contents [13].
Thus, this study examines relationships between basal and
insulin-stimulated mitochondrial function, glucose disposal,
and ectopic lipids in patients with T2DM and healthy
controls. We employed multinuclear MRS to quantify ATP
synthetic ﬂux, intracellular phosphorus metabolites (G-6-P
and inorganic phosphate [Pi]), IMCL, and hepatocellular
lipids (HCL) in combination with the stable isotope dilution
technique to assess glucose ﬂuxes during normoglycemic–
and hyperglycemic–hyperinsulinemic clamps.
Methods
Volunteers
Thirty-one volunteers were included in this study: (i)
patients with metabolically well-controlled T2DM, (ii) sex-,
age-, body mass index (BMI)-matched older volunteers with-
out diabetes (CONo) (age: 95% CI 52–63 y), and (iii) younger
individuals without diabetes (CONy) (age: 95% CI 25–28 y).
Their anthropometrical and laboratory characteristics are
summarized in Table 1. All participants were recruited by
means of public advertisement and underwent a complete
medical history, clinical examination, and lab tests to exclude
cardiovascular, hepatic, renal, and thyroid diseases. Patients
with diabetes on insulin treatment or presenting with islet
cell antibodies and diabetes-related complications were
excluded. Five patients with T2DM had a conﬁrmed family
history of diabetes. The individuals in the control groups
(CON) had neither a family history of diabetes nor were
taking any medication on a regular basis. Normal glucose
metabolism was conﬁrmed by a standard oral 75 g glucose
tolerance test. None of the participants performed intense
exercise on a regular basis. Physical activity was assessed with
a self-administered questionnaire of habitual physical activity
[14]. This questionnaire discriminates between three features
of physical activity: (i) physical activity at work (ii) sport
during leisure time and (iii) physical activity during leisure
time excluding sports. Average physical activity was calcu-
lated as the mean value across these features. The protocol
was approved by the local institutional ethics board, and
informed consent was obtained from each volunteer after
explanation of the purpose, nature, and potential complica-
tions of the study.
Experimental Protocol
All participants were on an isocaloric diet, refrained from
any physical exercise for 3 d prior to the study day, and fasted
for 12 h before the start of the experiment. Glucose-lowering
medication was withdrawn for at least 3 d before the
experiment. All studies were started at 6:30 a.m. with the
insertion of catheters (Vasoﬁx; Braun, http://www.bbraun.
com/index.cfm) in the antecubital veins of both arms for
blood sampling and infusions. A primed-continuous infusion
for 5 min ([3.6 mg fasting glucose (mg/dl)/90 (mg/dl)]/[min3kg
body weight]); and for 480 min (0.036 mg/[min 3 kg body
weight]) of D-[6,6-
2H2]glucose (98% enriched; Cambridge
Isotope Laboratories, http://www.isotope.com/cil/index.cfm)
was performed until the end of the clamp test to determine
endogenous glucose production (EGP). At 7:00 a.m., all
participants were transferred to the Magnetic Resonance
Unit to measure IMCL, G-6-P, and ﬂux through ATP synthase
in calf muscle using
1H/
31P MRS. After basal measurements,
the clamp test was started at 10:00 a.m. to create conditions of
normoglycemia (approximately 5.5 mmol/l glucose) and
hyperinsulinemia (approximately 500 pmol/l insulin). Insulin
(Actrapid; Novo Nordisk, http://www.novonordisk.com/) was
administered as a primed-continuous infusion (40 mU/[m
2
body surface area3min]) from 0 to 360 min. A 20% dextrose
infusion labeled with D-[6,6-
2H2]glucose (2% enriched)
according to the hot glucose infusion (hot GINF) protocol
was periodically adjusted to maintain normoglycemia [15].
Whole body insulin sensitivity was assessed from whole-body
glucose disposal (M) during the last 30 min of the clamp.
31P
MRS measurements (G-6-P, Pi, ATP synthesis) were repeated
between 120 min and 240 min. Four of the patients with
T2DM (three males and one female, mean values 6 SD: age,
62 6 2 y, BMI, 27.5 6 3 kg/m
2; M, 4.8 6 2.5 mg/(min3kg body
weight) underwent an additional hyperglycemic (approxi-
mately 9.5 mmol/l glucose) –hyperinsulinemic (approximately
500 pmol/l insulin) clamp test on a separate day to examine
the combined effect of insulin and glucose on G-6-P and ATP
synthesis.
Magnetic Resonance Spectroscopy
Measurements were performed on participants lying
supine inside a 3-T spectrometer (Bruker, http://www.
bruker.com/) using a 10 cm circular double resonant surface
coil for
1H and
31P measurements, positioned approximately
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as described previously [13].
31P MRS
31P spectra were acquired at baseline ( 100 to 20 min) and
during the last 80 min of the clamp. Rates of basal and
insulin-stimulated skeletal muscle ATP synthetic ﬂux (bfATP
and ifATP, respectively) were assessed with
31P MRS using the
saturation transfer experiment applied to the exchange
between Pi and ATP [11,13,16]. Intramyocellular concentra-
tions of G-6-P (lmol/l muscle) and Pi were measured from the
ratio of the integrated respective peak intensities and b-ATP
resonance intensity in spectra without inversion and satu-
ration assuming a constant ATP concentration of 5.5 mmol/l
muscle [2].
1H MRS
IMCL in soleus muscle was determined by
1H MRS as
described [1]. The cubic volume of interest within the muscle
(1.73 cm
3) and the magnetic ﬁeld was shimmed on the
localized water signal (line width, 2–15 Hz). On a separate day
and after a 12-h fast, localized
1H MRS of the liver was
acquired to measure HCL as described [17].
Analytical Procedures
Plasma glucose was measured by the glucose oxidase
method (Glucose analyzer II, Beckman Coulter, http://www.
beckmancoulter.com/). Plasma FFAs were assayed with a
microﬂuorimetric method (Wako Chem USA, http://www.
wakousa.com/). In vitro lipolysis was prevented by collecting
blood into orlistat-containing vials. Plasma triglycerides were
measured by a peroxidase-coupled colorimetric assay (Roche,
http://www.roche.com/home.html). Plasma concentrations of
insulin, C-peptide and glucagon were determined by double
antibody radioimmunoassay [15]. Plasma lactate concentra-
tions were measured enzymatically (Roche) [17].
Calculations and Statistics
Basal rates of glucose appearance (Ra) were calculated by
dividing the tracer D-[6,6-
2H2] glucose infusion rate times
tracer enrichment by the percent of tracer enrichment in
plasma and subtracting the tracer infusion rate [18]. Ra was
calculated using Steele’s nonsteady-state equations [19]. EGP
was calculated from the difference between Ra and mean
glucose infusion rates. Suppression of EGP (DEGP) by insulin
is given as the percent change of EGP at 240 min from fasting.
Suppression of plasma FFAs by insulin was calculated
analogous to EGP.
All statistical analyses were performed using SPSS 6.0
software (SPSS, http://www.spss.com). Data are presented as
means 6 standard deviations (SDs) throughout the text and
in the ﬁgures. Statistical comparisons between study groups
were performed using ANOVA and repeated measurements
ANOVA with Tukey post hoc testing when appropriate.
Within-group differences were determined using two-tailed
Student’s t tests. Non-parametric correlations are Spearman
correlations (R, P). Multiple linear regression analysis was
performed for the dependent variable, bfATP, including the
following basal metabolic parameters: C-peptide, alanine
aminotransferase, HbA1c, fasting plasma glucose, basal FFAs,
basal EGP, M, HCL, IMCL, basal G-6-P, activity index, BMI,
waist-to-hip ratio, and age. Regression analysis for the
dependent variable, ifATP, was done using the following
independent variables: DEGP, suppression of FFAs and
increase in G-6-P during clamp, M, HCL, IMCL, activity
index, BMI, waist-to-hip ratio, and age. Differences were
considered signiﬁcant at the 5% level.
Table 1. Clinical Characteristics of Volunteers
Variable T2DM CONo CONy
n (female/male) 5/5 5/5 2/9
Age (y) 59 6 6 (44–66)
a 57 6 6 (46–65)
a 27 6 2 (21–28)
BMI (kg/m
2)2 7 6 3 (22–32)
b 26 6 3 (20–30) 23 6 2 (20–26)
Waist-to-hip ratio 0.95 6 0.19 (0.83–1.03)
b 0.90 6 0.1 (0.71–1.01) 0.81 6 0.1 (0.69–0.87)
Physical activity index 2.7 6 0.4 (2.5–3.1) 2.9 6 0.4 (2.8–3.8) 2.8 6 0.3 (2.4–3.3)
PW 2.7 6 0.7 (1.6–3.8) 2.8 6 0.6 (2.4–3.8) 2.3 6 0.5 (1.3–3.0)
PS 2.9 6 0.7 (2.1–4.0) 3.0 6 0.9 (1.8–4.3) 2.8 6 0.9 (2.0–4.3)
PL 2.6 6 0.6 (1.9–3.8) 2.8 6 0.7 (1.8–3.8) 3.2 6 0.5 (2.5–4.0)
HbA1c (%) 6.9 6 0.7 (6.0–7.9)
a,c 5.5 6 0.3 (5.3–6.0) 5.2 6 0.2 (4.8–5.4)
FPG (mmol/l) 8.6 6 1.5 (6.9–12.4)
d 5.1 6 0.6 (4.6–5.7) 4.6 6 0.5 (4.3–5.2)
FPI (pmol/l) 75 6 32 (13–112) 62 6 17 (40–98) 61 6 17 (53–102)
TG (mmol/l) 1.25 6 0.5 (0.3–1.7) 1.4 6 0.6 (0.7–2.2) 0.85 6 0.3 (0.5–1.3)
FFAs (mmol/l) 0.53 6 0.18 (0.27–0.85) 0.49 6 0.29 (0.09–0.89) 0.31 6 0.25 (0.03–0.78)
HDL (mmol/l) 1.6 6 0.3 (1.2–2.3) 1.6 6 0.3 (1.2–2.1) 1.6 6 0.3 (1.3–2.0)
LDL (mmol/l) 3.4 6 0.8 (2.3–4.3) 3.8 6 0.9 (2.5–6.0)
e 2.6 6 0.4 (1.7–3.2)
ALT (U/l) 29 6 11 (14–41)
e 21 6 7 (6–33) 18 6 5 (13–32)
Anthropometric and laboratory characteristics, expressed as means 6 SDs (ranges), of patients with T2DM, CONo controls, and CONy controls. Physical activity index was assessed
according to Baecke et al. [14] and is given as the mean of the indices for physical activity at work (PW), sport during leisure time (PS) and physical activity during leisure time excluding
sport (PL). The physical activity index ranges from 2.4 to 3.0 with higher values indicating higher activity. BMI, waist circumference, fasting plasma glucose (FPG) and insulin (FPI),
triglycerides (TG), FFAs, high- and low-density lipoproteins (HDL, LDL), and alanine amino transferase (ALT) were determined.
ap , 0.001 versus CONy.
bp , 0.005 versus CONy.
cp , 0.001 versus CONo.
dp , 0.001 T2DM versus CONo and CONy.
ep , 0.01 versus CONy.
doi:10.1371/journal.pmed.0040154.t001
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Baseline Characteristics
Volunteers in the T2DM group were nonobese, normolipi-
demic, and metabolically well-controlled with stable HbA1c
values over the course of the last two years (Table 1). Basal
EGP was not different from controls (T2DM, 1.8 6 0.4 mg/[kg
body weight 3 min]; CONo, 1.9 6 0.3 mg/[kg body weight 3
min]; CONy, 1.7 6 0.6 mg/[kg body weight 3 min]; p ¼ 0.858).
Whole Body Metabolism During Normoglycemic-
Hyperinsulinemic Clamps
Fasting plasma glucose was higher in patients with T2DM
but normalized during the ﬁrst 30 min of the clamps (Figure
1). In patients with T2DM, fasting plasma C-peptide was 61%
higher than in both control groups (T2DM, 1.2 6 0.3 nmol/l;
CONo, 0.8 6 0.1 nmol/l; CONy, 0.7 6 0.1 nmol/l; p , 0.001
versus T2DM). Nevertheless, fasting plasma insulin was
comparable in all groups (Table 1). During the clamps, mean
concentrations of glucose and insulin were 5.5 6 0.5 mmol/l
and 514 6 96 pmol/l, respectively, and did not differ between
the groups (Figure 1). Fasting plasma lactate was lower (p ¼
0.005) in the CONy group than in patients with T2DM
(T2DM, 1.26 6 0.41 mmol/l; CONo, 1.01 6 0.25 mmol/l;
CONy, 0.80 6 0.25 mmol/l). During the clamp, lactate
concentrations remained unchanged in patients with T2DM,
gradually increased in the CONo participants (p ¼0.075) and
increased in the CONy participants by 56% (p ¼ 0.017)
(T2DM, 1.30 6 0.77 mmol/l; CONo, 1.29 6 0.39 mmol/l;
CONy, 1.24 6 0.11 mmol/l). Insulin-mediated suppression of
FFAs was comparable in all groups (T2DM, 92 6 6%; CONo,
95 6 4%; CONy, 90 6 8%), although patients with T2DM had
slightly higher plasma FFAs at 60, 180, and 210 min; p , 0.05
(Figure 1).
Insulin-stimulated whole body glucose disposal (M) was
126% and 54% higher in CONy and CONo participants than
in patients with T2DM, respectively (p , 0.001, p ¼ 0.010)
(Figure 2). Insulin-stimulated suppression of EGP was more
pronounced in CONy participants than in patients with
T2DM (DEGP: T2DM, 88% 6 8%; CONo, 91% 6 21%;
CONy, 107% 6 14%; p , 0.032 T2DM versus CONy).
Intracellular Metabolites
IMCL did not differ between the groups (T2DM, 1.0% 6
0.5%; CONo, 0.9% 6 0.5%; CONy, 0.9% 6 0.3%; p ¼ 0.808)
(Figure 2), whereas HCL were 4- to 7-fold higher in patients
with T2DM (T2DM, 14.1% 6 8.3%; CONo, 3.3% 6 4.4%;
CONy, 2.2% 6 1.8%; p , 0.001 versus T2DM).
Intramyocellular G-6-P concentrations were similar during
fasting (0.15 6 0.057 mmol/l muscle) and increased by 50%
during the clamp in all groups (0.22 6 0.071 mmol/l muscle:
T2DM, p ¼ 0.044 versus baseline; CONo, p ¼ 0.009 versus
baseline; CONy, p ¼ 0.002 versus baseline). Likewise, intra-
myocellular Pi concentrations were comparable at baseline
(2.9 6 0.4 mmol/l muscle) and increased 17% during the
clamp in all groups (3.4 6 0.4 mmol/l muscle: T2DM, p¼0.005
versus baseline; CONo, p ¼ 0.001 versus baseline; CONy, p ¼
0.004 versus baseline).
Rates of Muscle ATP Synthesis
bfATP was 27% lower in patients with T2DM than in CONy
participants (T2DM, 8.6 6 1.9 lmol/[g muscle 3 min]; CONy,
11.8 6 3.3 lmol/[g muscle3min] p , 0.031) and did not differ
from CONo participants (10.4 6 2.6 lmol/[g muscle3min]; p
¼ 0.293 versus T2DM and p ¼ 0.505 versus CONy) (Figure 3).
ifATP rose by 26% and 11% in the CONy participants (14.8
6 4.3 lmol/[g muscle 3 min], p ¼ 0.003 versus basal) and the
CONo participants (11.5 6 1.7 lmol/[g muscle 3 min], p ¼
0.023 versus basal), but not in patients with T2DM (9.5 6 2.7
lmol/[g muscle 3 min], p ¼ 0.256 versus basal). Signiﬁcant
associations between ATP synthesis rates and physiological
variables are shown in Table 2 and Figure 4. Fasting plasma
insulin levels neither related to bfATP, ifATP, nor to M. C-
peptide related negatively to ifATP (R¼ 0.458, p¼0.010) and
positively to M (R ¼ 0.550, p ¼ 0.001). Adjustment for M
disrupted the association between ATP synthetic ﬂuxes and
C-peptide levels. Adjustment for sex, age, BMI, and waist-to-
hip ratio did not disrupt the negative correlations of bfATP
and ifATP with fasting FFAs (R¼ 0.533, p¼0.007; R¼ 0.408,
p¼0.042) and of ifATP to HCL (R¼ 0.415, p¼0.044). bfATP
correlated positively with mean physical activity (R¼0.945, p
, 0.001) and negatively with BMI (R¼ 0.818, p¼0.004) only
in patients with T2DM. Multiple linear regression analysis for
the dependent variable bfATP including basal metabolic
parameters (see Methods) identiﬁed basal plasma FFAs and
waist-to-hip ratio as signiﬁcant and independent predictors
of bfATP (Table 3). In model 1, basal FFAs alone explained
28% of the variance of bfATP. In model 2, waist-to-hip ratio
was included in addition to basal plasma FFAs, thereby
explaining 44% of the variance of bfATP. Multiple regression
analysis for the dependent variable ifATP identiﬁed insulin
sensitivity (M) as a signiﬁcant predictor and explained 30% of
the variance of ifATP (Table 3).
Whole Body Metabolism During Hyperglycemic-
Hyperinsulinemic Clamps
The effect of combined glucose and insulin stimulation on
ifATP was studied in four of the T2DM volunteers during
hyperglycemic–hyperinsulinemic clamps (Figure 5). Mean
plasma glucose almost doubled (9.6 6 0.8 mmol/l versus 5.5
6 0.3 mmol/l; p , 0.001) resulting in 70% higher M-values
compared to normoglycemic hyperinsulinemia (8.1 6 4.4 mg/
[kg body weight3min] versus 4.8 6 2.5 mg/[kg body weight3
min]; p ¼ 0.048). Intramyocellular G-6-P concentrations
doubled compared to normoglycemic hyperinsulinemia (240
min: 0.29 6 0.01 mmol/l muscle versus 0.15 6 0.05 mmol/l
muscle; p ¼ 0.010). Mean bfATP, ifATP and change of fATP
during insulin stimulation did not differ between normogly-
cemic and hyperglycemic clamps (bfATP: 9.5 6 2.2 lmol/[g
muscle 3 min] versus 8.1 6 1.7 lmol/[g muscle 3 min], p ¼
0.506; ifATP: 10.3 6 2.4 lmol/[g muscle 3 min] versus 8.6 6
3.2 lmol/[g muscle 3 min], p ¼ 0.156, p ¼ 0.628 basal versus
insulin stimulation during hyperglycemic–hyperinsulinemic
clamp; change of fATP during insulin stimulation: 0.9 6 3.3
lmol/[g muscle 3 min] versus 0.03 6 1.8 lmol/[g muscle 3
min], p ¼ 0.579).
Discussion
Patients with well-controlled T2DM have impaired ﬂux
through muscle ATP synthesis occurring independently of
glucose transport/phosphorylation and lipid deposition.
Lipid availability primarily determines bfATP, whereas
insulin sensitivity deﬁnes ifATP. Furthermore, the reduction
in insulin-stimulated glucose disposal despite normal glucose
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mainly in glycogen synthesis of these patients with T2DM.
We studied slightly overweight patients with well-con-
trolled T2DM featuring a lower degree of whole-body insulin
resistance compared with previous studies on mitochondrial
function in insulin resistant states [9,20,21]. Of note, BMI,
waist-to-hip ratio, fasting lipid, and insulin concentrations
were comparable to an age-matched control group. These
patients with overt T2DM exhibit somewhat reduced
muscular ATP synthesis as assessed by noninvasive in vivo
31P MRS.
Fasting Conditions
Both control groups featured similar bfATP, which was
nearly doubled compared to a group of participants who
were 15 years older, in a previous study [11]. Thus, aging-
dependent alterations in mitochondrial number, morphol-
ogy, and in vivo function do not seem to be present in our
CONo group, but cannot be completely excluded, because we
did not perform muscle biopsies in this study [5,11,22]. bfATP
of the patients with T2DM was higher than in other insulin-
resistant groups, but lower only compared to the CONy
group [11,12,23]. This variation suggests that nondiabetic
insulin-resistant groups, such as ﬁrst-degree relatives of
patients with T2DM, exhibit peculiar abnormalities in bfATP
which can be confounded by secondary metabolic events in
the overt diabetic state. Physical activity and body mass were
the major determinants of bfATP only in the patients with
T2DM, conﬁrming the relationship between exercise training
and mitochondrial function and further pointing to a speciﬁc
susceptibility of mitochondrial function to lifestyle factors in
patients with T2DM [24].
Fasting plasma FFAs and waist-to-hip ratio were identiﬁed
as independent predictors of bfATP. FFAs could decrease
ATP synthesis by protonophoric action on the inner
mitochondrial membrane, activation of uncoupling protein-
1 (UCP-1), and damage of mitochondrial proteins and DNA,
Figure 1. Plasma Glucose, Insulin and FFAs
Time course of plasma glucose (top), insulin (middle), and FFAs (bottom)
concentrations during euglycemic (approximately 5.5 mM glucose) –
hyperinsulinemic (approximately 500 pM insulin) clamps in patients with
T2DM (n ¼ 10) (diamonds), age- and BMI-matched controls (CONo; n ¼
10) (squares), and young healthy controls (CONy; n ¼ 11) (triangles). All
units expressed as means 6 SD. * p , 0.05 T2DM versus controls.
doi:10.1371/journal.pmed.0040154.g001
Figure 2. Glucose Metabolism and Intracellular Lipids of Skeletal Muscle
and Liver
Whole-body glucose disposal (A) and DEGP (B) during euglycemic–
hyperinsulinemic clamp (n¼31). IMCL in skeletal muscle (n¼31) (C) and
liver (n¼29) (HCL) (D). Patients with T2DM (black columns), CONo (grey
columns), and CONy (white columns). All results are means 6 SD. { p ,
0.001 T2DM versus CONy;
 p , 0.01 CONo versus T2DM and CONy; * p ,
0.05 T2DM versus CONy; § p , 0.001 T2DM versus controls.
doi:10.1371/journal.pmed.0040154.g002
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Lipid-induced dysfunction of mitochondria might also occur
via down-regulation of nuclear genes involved in genes that
are involved in oxidative phosphorylation (OXPHOS) and
mitochondrial biogenesis [29]. Thus, environmental factors
could serve as an epigenetic trigger affecting mitochondrial
biogenesis in patients with T2DM [30]. The frequently
observed inverse association between lipid accumulation in
skeletal muscle and insulin sensitivity is inﬂuenced by various
factors such as gender, ethnicity, genes, and total body fat
content, and it depends on muscle ﬁber composition [1]. In
the present study, IMCL did not differ between groups,
suggesting that FFAs and their intracellular metabolites,
rather than lipid deposition, are related to mitochondrial
function.
Despite their good long-term metabolic control, the
patients with T2DM were hyperglycemic during bfATP
measurements due to withdrawal of glucose-lowering medi-
cation. Of note, transcription of OXPHOS genes can be
normalized by near-normoglycemia in patients with poorly
controlled T2DM [31]. Hyperglycemia also increases reactive
oxygen species formation due to an imbalance between
glucose phosphorylation by mitochondria-bound hexokinase
and reactions decreasing G-6-P such as glycolysis, pentose
phosphate shunt, and glycogen synthesis. The resulting rise in
G-6-P would cause feedback inhibition of hexokinase,
decrease the mitochondrial ADP:ATP ratio, and thereby
disrupt ADP recycling [32,33]. As fasting intramyocellular G-
6-P was not different between individuals with and without
diabetes, increased plasma glucose cannot completely ac-
count for the reduction of bfATP in patients with T2DM.
Insulin Stimulated Conditions
Although glucose disposal was markedly lower in patients
with T2DM than in the controls during insulin stimulation,
the 50% increase in G-6-P was surprisingly comparable
between all three groups. Hyperinsulinemia of 515 pmol/l
resulted in stimulation of glucose transport/phosphorylation
in patients with T2DM similar to that in persons who do not
have diabetes, and it rose even further during hyperglycemic
hyperinsulinemia. The rise in G-6-P in the face of impaired
glucose disposal could result from a defect of either glucose
oxidation or glycogen synthesis relative to glucose transport
via GLUT-4 and/or phosphorylation (hexokinase II), both of
which lead to reduction of insulin-stimulated ATP synthesis.
Glucose transport was shown to be rate controlling for
glucose disposal at lower plasma insulin concentrations and
in obese patients with poorly controlled T2DM [34]. Reduced
expression and/or ﬂux through hexokinase II indicate that
glucose phosphorylation can also be impaired in patients
with T2DM [32]. One might speculate that the insulin-
induced rise in G-6-P observed in our patients with T2DM
could have reduced the activity of hexokinase II and lower the
ADP:ATP ratio which in turn would slow down stimulation of
ATP synthase ﬂux [35]. However, both absolute concentra-
tions and percentage increase of G-6-P were almost identical,
rendering this possibility unlikely. Thus, the insulin-sensitive
rise in G-6-P seems to depend critically on the degree of
insulinemia and glycemia and probably also on long-term
metabolic control. These mechanisms could explain why a 20-
fold rise in plasma insulin concentrations during hyper-
glycemia completely normalizes the diminished insulin-
stimulated increment in G-6-P of patients with poorly
controlled T2DM [36]. On the other hand, lean insulin-
resistant relatives of patients with T2DM exhibit a markedly
reduced insulin-sensitive rise in G-6-P despite normoglyce-
mia, highlighting the predominant role of inherited factors
also for glucose transport/phosphorylation in this group [35].
Our patients with T2DM exhibited 27% lower rates of
fasting ATP synthetic ﬂux than the CONy participants,
suggesting reduced aerobic capacity in T2DM. Reduction of
oxidative capacity during insulin stimulation would diminish
glucose oxidation—as reﬂected by impaired stimulation of
ATP synthesis—and simultaneously cause reduction of
glucose disposal. Plasma lactate was slightly higher during
Figure 3. Rates of ATP Synthetic Flux
Rates of ATP synthetic flux (means 6 SD) during fasting (bfATP, full
columns) and during insulin stimulation (ifATP, hatched columns).
Patients with T2DM (black columns), CONo controls (grey columns)
and CONy controls (white columns) (n ¼ 31). § p , 0.05 T2DM versus
CONy; *, p , 0.05;
, p , 0.01.
doi:10.1371/journal.pmed.0040154.g003
Table 2. Associations between ATP Synthesis Rates and
Physiological Variables
Variable bfATP ifATP
HbA1c R ¼  0.417, p ¼ 0.019 R ¼  0.453, p ¼ 0.010
M R ¼ 0.488, p ¼ 0.005 R ¼ 0.587, p ¼ 0.001
Basal FFAs R ¼  0.462, p ¼ 0.009 R ¼  0.482, p ¼ 0.006
HCL R ¼  0.290, p ¼ 0.127 R ¼  0.434, p ¼ 0.019
Spearman correlation coefficients (R) for the association of bfATP and ifATP with insulin
sensitivity during the clamp test (M), fasting FFAs, HCL, and HbA1c. Insulin sensitivity was
calculated from whole-body glucose disposal (M) during the last 30 min (210–240 min) of
a normoglycemic-hyperinsulinemic clamp.
doi:10.1371/journal.pmed.0040154.t002
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drate oxidation was therefore likely unchanged, although
abnormalities cannot be ruled out, because plasma lactate
levels are also determined by extramuscular sources such as
adipocytes [37].
In our patients with T2DM, impaired glucose disposal
despite intact glucose transport/phosphorylation could fur-
ther mirror a defect in insulin-stimulated nonoxidative
glucose metabolism, i.e., muscle glycogen synthesis. In
insulin-resistant nonobese relatives of patients with T2DM,
exercise training unmasks an independent abnormality in
muscle glycogen synthesis as shown by doubling of insulin-
stimulated G-6-P without normalization of nonoxidative
glucose metabolism [38]. One limitation of the present study
resides in the lack of data on muscle glycogen synthesis, which
could not be measured due to time restrictions in this
protocol. Nevertheless, the available data suggest a distinct
post-transport/phosphorylation defect, particularly in glyco-
gen synthesis, in these patients with well-controlled T2DM
[39–41]. Another limitation resides in the small sample size of
this study, which affects the probability of detecting
associations between parameters and differences between
groups. Of note, some normality approximations do not
necessarily hold true for small numbers.
In young healthy humans, insulin markedly stimulated ATP
synthesis, which primarily results from augmented substrate
availability, mainly glucose, and stimulation of respiratory
chain enzyme activities within 1–3 h of hyperinsulinemia, and
from increased mitochondrial protein expression after 6 h of
prolonged hyperinsulinemia [7,13,23]. ATP synthesis rose
only modestly in CONo participants (11%) but not in patients
with T2DM. Despite the known age-related mitochondrial
abnormalities, in vivo mitochondrial function can be main-
tained in humans up to 70 years of age depending on physical
activity and body mass [42,43]. Likewise, insulin sensitivity can
be unimpaired but also reduced upon correction for body
mass in the elderly [11,44–46]. In the present study, adjust-
ment for BMI and waist-to-hip ratio did not affect the
association between age and insulin sensitivity (R ¼  0.634, p
, 0.001). Moreover, the lower increase in ifATP in our elderly
participants is in line with the previously observed simulta-
neous occurrence of decreased basal ATP synthesis and
decreased insulin sensitivity, and supports the contention
that age-dependent changes in ifATP relate to those of
insulin sensitivity [11].
The participants with T2DM, to which the controls were
matched for age and BMI, failed to exhibit an increase in
ifATP, similar to recent ﬁndings in young nonobese insulin-
resistant offspring of patients with T2DM. Thus, it can be
Figure 4. Associations between ATP Synthetic Flux and Metabolic
Parameters
Correlation analyses of rates of ATP synthetic flux (n ¼ 31).
(A) Relation between fasting plasma concentration of FFAs and bfATP
across all groups.
(B) Relation between fasting plasma FFAs and ifATP across all groups.
Patients with T2DM (n¼10) (diamonds), age- and BMI-matched controls
(CONo; n ¼ 10) (squares), and young healthy controls (CONy; n ¼ 11)
(triangles).
doi:10.1371/journal.pmed.0040154.g004
Table 3. Multiple Regression Analysis for the Dependent Variables bfATP and ifATP
Dependent Variable Model Constant R
2 Adjusted R
2 Standardized Coefficient (b) p-Value
bfATP 1 Basal FFAs 0.282 0.254  0.531 0.004
2 Basal FFAs 0.438 0.392  0.599 0.001
Waist to hip ratio  0.401
ifATP 1 Insulin sensitivity 0.303 0.274 0.550 0.004
Coefficients of the models explaining bfATP and ifATP variations.
doi:10.1371/journal.pmed.0040154.t003
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impaired ATP synthesis during insulin stimulation, which is
supported by the multivariate analyses across all groups in
the present study. The nonobese patients with T2DM
featured defective ifATP despite normal G-6-P stimulation,
suggesting an abnormality independent of glucose transport
that does not disappear by matching glucose disposal to that
of older controls and resulting in doubling of G-6-P by
hyperglycemic hyperinsulinemia.
Intramuscular Pi concentrations increased by 17%, in
agreement with previous studies [47]. The ﬁnding of similar
basal and insulin-stimulated Pi in all groups seems to exclude
abnormal Pi transport as the explanation for the ifATP
variability in patients with T2DM. In contrast, lean insulin-
resistant relatives of patients with T2DM exhibit markedly
decreased insulin-stimulated Pi transport [23]. The difference
between this group and our patients with overt T2DM could
result from speciﬁc inherited mitochondrial abnormalities in
the relatives or secondary metabolic changes obscuring the
effect on Pi transport in the patients with T2DM. Alter-
natively, increased lipid availability could explain lower
ifATP by interference with insulin signaling, which is in line
with FFA-dependent ifATP inhibition [13]. Of note, plasma
levels of FFAs during fasting was found to be tightly related
to both bfATP and ifATP in the present study. Finally, ifATP
correlated with HCL and elevation of HCL was identiﬁed as
an early abnormality in patients with well-controlled T2DM,
supporting the concept that ectopic fat in the liver rather
than in muscle relates to whole body insulin sensitivity [48].
Different variants of insulin resistance can be found in
humans. Insulin-resistant lean normoglycemic relatives of
patients with T2DM present with IMCL accumulation along
with clearly impaired insulin-stimulated Pi transport, mito-
chondrial ATP synthesis, and glucose transport and/or
phosphorylation. In contrast, insulin-resistant nonobese
near-normoglycemic patients with T2DM exhibit only slightly
reduced ATP synthesis but have completely normal IMCL, Pi
transport, and G-6-P increase. The difference could be
explained by genes and secondary metabolic alterations such
as glucolipotoxicity affecting the patients with T2DM.
However, comparable fasting lipid concentrations and body
mass in patients with T2DM and the age-matched control
group render the latter possibility unlikely. To which extent
accumulation of ectopic lipids (particularly HCL, which is
seen in both offspring of and patients with overt T2DM) serve
as common mediators or indicators of insulin resistance
regardless of muscular abnormalities requires further inves-
tigation.
In conclusion, (i) patients with well-controlled insulin
resistant T2DM have slightly lower ATP synthesis independ-
ent of glucose transport/phosphorylation and lipid deposi-
tion in muscle, (ii) lipid availability primarily determines
bfATP, whereas (iii) insulin sensitivity deﬁnes ifATP, and (iv)
reduction in insulin-stimulated glucose disposal suggests
further abnormalities, mainly in glycogen synthesis of these
patients with T2DM.
Figure 5. Glucose Metabolism and ATP Synthetic Flux during Hyper-
glycemic–Hyperinsulinemia in T2DM
Whole body glucose disposal (A), concentration of intramyocellular G-6-P
(B), and ifATP (C) during euglycemic (approximately 5.5 mM glucose)–
hyperinsulinemic (approximately 500 pM insulin) (white columns) and
hyperglycemic (approximately 9.5 mM glucose)–hyperinsulinemic (ap-
proximately 500 pM insulin) clamps (hatched columns) in patients with
T2DM (n ¼ 4). * p , 0.05.
doi:10.1371/journal.pmed.0040154.g005
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ATP Synthesis in Type 2 DiabetesThis study underlines the strong relationship between
insulin sensitivity and function of mitochondria, the cells’
power plants. Even a small degree of overweight and physical
inactivity is associated with reduction in mitochondrial
function, conﬁrming the importance of lifestyle for develop-
ment and prevention of insulin resistance and T2DM. Further
research is needed, however, to delineate whether abnormal-
ities in mitochondrial number and/or function are the cause
or consequence of T2DM and to address the mitochondria as
a target for novel therapeutic regimens.
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Editors’ Summary
Background. Diabetes mellitus is an increasingly common chronic
disease characterized by high blood sugar (glucose) levels. In normal
individuals, blood sugar levels are maintained by the hormone insulin.
Insulin is released by the pancreas when blood glucose levels rise after
eating (glucose is produced by the digestion of food) and ‘‘instructs’’
insulin-responsive muscle and fat cells to take up glucose from the
bloodstream. The cells then use glucose as a fuel or convert it into
glycogen, a storage form of glucose. In type 2 diabetes, the commonest
type of diabetes, the muscle and fat cells become nonresponsive to
insulin (a condition called insulin resistance) and consequently blood
glucose levels rise. Over time, this hyperglycemia increases the risk of
heart attacks, kidney failure, and other life-threatening complications.
Why Was This Study Done? Insulin resistance is often an early sign of
type 2 diabetes, sometimes predating its development by many years, so
understanding its causes might provide clues about how to stop the
global diabetes epidemic. One theory is that mitochondria—cellular
structures that produce the energy (in the form of a molecule called ATP)
needed to keep cells functioning—do not work properly in people with
insulin resistance. Mitochondria change (metabolize) fatty acids into
energy, and recent studies have revealed that fat accumulation caused
by poorly regulated fatty acid metabolism blocks insulin signaling, thus
causing insulin resistance. Other studies using magnetic resonance
spectroscopy (MRS) to study mitochondrial function noninvasively in
human muscle indicate that mitochondria are dysfunctional in people
with insulin resistance by showing that ATP synthesis is impaired in such
individuals. In this study, the researchers have examined both baseline
and insulin-stimulated mitochondrial function in nonobese patients with
well-controlled type 2 diabetes and in normal controls to discover more
about the relationship between mitochondrial dysfunction and insulin
resistance.
What Did the Researchers Do and Find? The researchers determined
the insulin sensitivity of people with type 2 diabetes and two sets of
people (the ‘‘controls’’) who did not have diabetes: one in which the
volunteers were age-matched to the people with diabetes, and the other
containing younger individuals (insulin resistance increases with age). To
study insulin sensitivity in all three groups, the researchers used a
‘‘hyperinsulinemic–euglycemic clamp.’’ For this, after an overnight fast,
the participants’ insulin levels were kept high with a continuous insulin
infusion while blood glucose levels were kept normal using a variable
glucose infusion. In this situation, the glucose infusion rate equals
glucose uptake by the body and therefore measures tissue sensitivity to
insulin. Before and during the clamp, the researchers used MRS to
measure glucose-6-phosphate (an indicator of how effectively glucose is
taken into cells and phosphorylated), ATP synthesis, and the fat content
of the participants’ muscle cells. Insulin sensitivity was lower in the
patients with diabetes than in the controls, but muscle lipid content was
comparable and hyperinsulinemia increased glucose-6-phosphate levels
similarly in all the groups. Patients with diabetes and the older controls
had lower fasting ATP synthesis rates than the young controls and,
whereas insulin stimulation increased ATP synthesis in all the controls, it
had no effect in the patients with diabetes. In addition, fasting blood
fatty acid levels were inversely related to basal ATP synthesis, whereas
insulin sensitivity was directly related to insulin-stimulated ATP synthesis.
What Do These Findings Mean? These findings indicate that the
impairment of muscle mitochondrial ATP synthesis in fasting conditions
and after insulin stimulation in people with diabetes is not due to
impaired glucose transport/phosphorylation or fat deposition in the
muscles. Instead, it seems to be determined by lipid availability and
insulin sensitivity. These results add to the evidence suggesting that
mitochondrial function is disrupted in type 2 diabetes and in insulin
resistance, but also suggest that there may be abnormalities in glycogen
synthesis. More work is needed to determine the exact nature of these
abnormalities and to discover whether they can be modulated to
prevent the development of insulin resistance and type 2 diabetes. For
now, though, these findings re-emphasize the need for people with type
2 diabetes or insulin resistance to reduce their food intake to
compensate for the reduced energy needs of their muscles and to
exercise to increase the ATP-generating capacity of their muscles. Both
lifestyle changes could improve their overall health and life expectancy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040154.
  The MedlinePlus encyclopedia has pages on diabetes
  The US National Institute of Diabetes and Digestive and Kidney
Diseases provides information for patients on diabetes and insulin
resistance
  The US Centers for Disease Control and Prevention has information on
diabetes for patients and professionals
  American Diabetes Association provides information for patients on
diabetes and insulin resistance
  Diabetes UK has information for patients and professionals on
diabetes
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